05 Nov 2026, 06:50 IST
Zydus Lifesciences Limited
HDFC Securities · ADD · target INR 1,280
The report notes EBITDA grew only 8% YoY despite 29% YoY sales growth due to higher operating costs, but maintains ADD citing steady India/US growth, R&D monetization and Medtech scale-up.
From HSIE Results Daily 05 Nov 26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.